Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Kelly on the Rationale for Combining Radium-223 and Niraparib in mCRPC

June 5th 2020

William Kevin Kelly, DO, discusses the rationale for a phase 1b dose-finding study evaluating the combination radium-223 dichloride and niraparib in patients with metastatic castration-resistant prostate cancer.

Dr. Klein on Predicting Tumor Aggressiveness With Oncotype DX Test in Prostate Cancer

June 4th 2020

Eric A. Klein, MD, discusses the Oncotype DX test and how it is utilized to predict tumor aggressiveness in patients with prostate cancer.

Dr. Chi on the Prostate Cancer Biomarker Enrichment and Treatment Selection Study

June 4th 2020

Kim Chi, MD, discusses prostate cancer biomarker enrichment and treatment selection study.

Some Types of Prostate Cancer May Not be as Aggressive as Originally Thought

June 4th 2020

Researchers at the UCLA Jonsson Comprehensive Cancer Center analyze gene-expression patterns in the most aggressive prostate cancer grade group—known as Gleason grade group 5—and found that this grade of cancer can actually be subdivided into four subtypes with distinct differences.

Dr. Katz on Redefining Risk Assessment in Prostate Cancer With 17-Gene Oncotype DX GPS

June 3rd 2020

Aaron E. Katz, MD, FACS, discusses re-classifying low-risk prostate scores with the 17-gene Oncotype DX Genomic Prostate Score.

Dr. Katz on Determining Low-Risk Disease in Prostate Cancer

June 2nd 2020

Aaron E. Katz, MD, FACS, discusses strategies for determining low-risk prostate cancer.

Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC

May 31st 2020

The use of cabazitaxel over abiraterone acetate or enzalutamide may continue as a standard of care in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents.

Cabozantinib Plus Atezolizumab Shows Promise in mCRPC

May 31st 2020

The combination of cabozantinib and atezolizumab showed clinically meaningful activity in patients with metastatic castration-resistant prostate cancer.

Darolutamide Improves OS, Delays Onset of Cancer-Related Morbidity and Subsequent Chemo in Nonmetastatic CRPC

May 31st 2020

Darolutamide (Nubeqa) plus androgen deprivation therapy led to a 31% reduction in the risk of death compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer.

Baseline and Posttreatment ctDNA Positivity Linked to Poor Prognosis, rPFS in mCRPC

May 31st 2020

Baseline and posttreatment circulating tumor DNA positivity was associated with worse radiologic progression-free survival in patients with metastatic castration-resistant prostate cancer.

Apalutamide Plus ADT Leads to Significantly Improved Outcomes in Nonmetastatic CRPC

May 31st 2020

Results from the phase III SPARTAN trial showed that apalutamide plus androgen deprivation therapy significantly improved overall survival when compared with ADT plus placebo in patients with nonmetastatic castration-resistant prostate cancer.

Diagnostic Performance of PSMA-Targeted PET Tracer Excels in Relapsed Prostate Cancer

May 30th 2020

Imaging with 18F-DCFPyL-PET/CT outperformed that of standard imaging modalities—such as bone scan, CT, MRI, and FDG PET—in patients with biochemically relapsed prostate cancer.

HERO Trial Suggests Relugolix to Become New Standard for T-Suppression in Advanced Prostate Cancer

May 30th 2020

Relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone (T)-suppression through 48 weeks in patients with advanced prostate cancer.

Phase II TheraP Trial Shows Promise for LuPSMA in mCRPC

May 29th 2020

Results from the TheraP trial found that in men with metastatic castration resistant prostate cancer who progressed after treatment with docetaxel, 177Lu-PSMA-617 was more active than cabazitaxel.

NCCN Adds Rucaparib to Prostate Cancer Guidelines

May 28th 2020

The National Comprehensive Cancer Network has updated its Prostate Cancer guidelines to include the PARP inhibitor rucaparib.

Study Links Decline in PSA Screening to Increased Incidence of Advanced Prostate Cancer

May 25th 2020

Decreases in local-stage and increases in distant- and regional-stage prostate cancer incidence may be the result of a recommendation by the US Preventive Services Task Force against PSA–based screenings.

Rucaparib Prostate Cancer Approval Sets Stage for Further Research

May 21st 2020

Alan H. Bryce, MD, discusses the recent regulatory approval of rucaparib in metastatic castration-resistant prostate cancer and explains how the approval has underscored the importance of genetic testing in the field.

Meta-Analysis Finds Adding ADT to EBRT Extends Survival in Localized Prostate Cancer

May 21st 2020

External beam radiotherapy plus androgen deprivation therapy showed superior overall survival compared with EBRT plus a brachytherapy boost in men with intermediate- and high-risk prostate cancer.

Dr. Klein on Oncotype DX in Predicting Outcomes in African Americans With Prostate Cancer

May 21st 2020

Eric A. Klein, MD, discusses the utility of Oncotype DX Genomic Prostate Score in predicting outcomes in African American men with prostate cancer.

FDA Approves Multiple Companion Diagnostics for Olaparib in HRR+ mCRPC

May 20th 2020

The FDA has approved the FoundationOneCDx and BRACAnalysis CDx tests as companion diagnostics to identify patients with metastatic castration-resistant prostate cancer with homologous recombination repair mutations, making them eligible for treatment with the PARP inhibitor olaparib.